{"organizations": [], "uuid": "3ecac382c2dea81b4dad711e1333292c2a0889d3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-crispr-therapeutics-reports-q1-los/brief-crispr-therapeutics-reports-q1-loss-per-share-0-62-idUSASC0A0GK", "country": "US", "domain_rank": 408, "title": "BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T15:19:00.000+03:00", "replies_count": 0, "uuid": "3ecac382c2dea81b4dad711e1333292c2a0889d3"}, "author": "", "url": "https://www.reuters.com/article/brief-crispr-therapeutics-reports-q1-los/brief-crispr-therapeutics-reports-q1-loss-per-share-0-62-idUSASC0A0GK", "ord_in_thread": 0, "title": "BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62", "locations": [], "entities": {"persons": [], "locations": [{"name": "crispr", "sentiment": "none"}], "organizations": [{"name": "brief-crispr therapeutics", "sentiment": "negative"}, {"name": "therapeutics ag", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "therapeutics ag", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crispr therapeutics ag", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 12:20 PM / Updated 18 minutes ago BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62 Reuters Staff\nMay 8 (Reuters) - CRISPR Therapeutics AG:\n* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* CRISPR THERAPEUTICS AG - ON TRACK TO BEGIN CTX001 CLINICAL STUDY IN HEMOGLOBINOPATHIES IN 2018\n* CRISPR THERAPEUTICS AG - ON TRACK TO FILE IND IN 2018 FOR CTX101, ALLOGENEIC CRISPR-BASED CAR-T TARGETED TOWARD CD19+ MALIGNANCIES\n* CRISPR THERAPEUTICS AG - TOTAL COLLABORATION REVENUES WERE $1.4 MILLION FOR Q1 OF 2018 COMPARED TO $2.7 MILLION FOR Q1 OF 2017\n* CRISPR THERAPEUTICS AG - QTRLY LOSS PER SHARE $0.62\n* CRISPR THERAPEUTICS AG - HAS $341.8 MILLION IN CASH AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-08T15:19:00.000+03:00", "crawled": "2018-05-08T15:40:01.000+03:00", "highlightTitle": ""}